Lundbeckfonden Ventures

Founded in 2022, Kvantify is headquartered in Copenhagen, Denmark. It specializes in quantum computing management software, offering solutions to address computational challenges across various industries such as life sciences, financial services, and logistics.

Notify Therapeutics is a biotechnology company focused on developing innovative therapies for infertility. Specifically, it targets the early, hormone-independent phase of egg maturation, aiming to create a first-in-class treatment for women who do not respond to standard hormone therapy. The company's approach involves utilizing drug-inducing factors that regulate the intracellular AKT pathway, facilitating ovarian follicle development. This non-hormonal treatment is particularly designed to assist women with low ovarian reserves, enhancing their chances of successful conception while minimizing the risks associated with multiple pregnancies.

WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Aura Biosciences is a clinical-stage biotechnology company founded in 2007 and based in Cambridge, Massachusetts. It develops cancer therapies using tumor-targeted pseudovirions, employing viral nanoparticles conjugated to infrared-activated molecules to selectively destroy cancer cells. The lead program AU-011 targets ocular melanoma, including primary choroidal melanoma, with the aim of treating tumors locally while reducing damage to surrounding tissue. The company pursues precision therapies for solid tumors and has ongoing development in other ocular oncology indications and bladder cancer, focusing operations in the United States.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

SNIPR Biome is a biotechnology company developing CRISPR-based therapies for treating microbial diseases. Founded in 2017 and headquartered in Copenhagen, Denmark, the company leverages CRISPR technology to selectively eliminate harmful bacteria by targeting their specific DNA sequences.

Tiburio Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, specializes in developing and manufacturing medicines for rare endocrine diseases and tumors related to the endocrine system. The company's primary focus is on TBR-760, a drug candidate designed to treat non-functioning pituitary adenoma (NFPA) using a dopamine-somatostatin chimeric molecule aimed at shrinking or halting tumor growth. Additionally, Tiburio explores other compounds like TBR-065 for treating rare endocrine diseases where effective treatments are limited.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

DYSIS Medical Ltd., established in 2002 and headquartered in Edinburgh, UK, specializes in designing, developing, manufacturing, and marketing non-invasive imaging systems for detecting cancerous and pre-cancerous lesions. Its flagship product is the DYSIS Colposcope, a digital colposcope that measures aceto-whitening reaction and generates an intuitive map for easier diagnosis. The company also offers accessories like disposable/reusable specula, diathermy loops, coagulation balls, and software for data management and DYSISmap development. With sales offices in Tampa (USA), Edinburgh (UK), and Athens (Greece), DYSIS Medical aims to improve healthcare outcomes globally.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Aura Biosciences is a clinical-stage biotechnology company founded in 2007 and based in Cambridge, Massachusetts. It develops cancer therapies using tumor-targeted pseudovirions, employing viral nanoparticles conjugated to infrared-activated molecules to selectively destroy cancer cells. The lead program AU-011 targets ocular melanoma, including primary choroidal melanoma, with the aim of treating tumors locally while reducing damage to surrounding tissue. The company pursues precision therapies for solid tumors and has ongoing development in other ocular oncology indications and bladder cancer, focusing operations in the United States.

Founded in 2003, Atox Bio is a biotechnology company specializing in immunomodulators for treating critically ill patients with severe infections. Its focus lies in developing novel modulators targeting key pathways of the adaptive and innate immune response to improve outcomes in critical care settings.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The company identifies and de-risks compounds that hold therapeutic and commercial potential, employing a rigorous process to generate data that supports both development pathways and the formation of new companies. With a team that boasts deep expertise in drug development and strong relationships within academia and patient advocacy, Cydan accelerates therapies through various stages, including clinical, regulatory, and commercial development. By facilitating the creation of effective treatments, Cydan aims to improve the lives of patients and families affected by rare diseases.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic products, particularly for patients with serious medical conditions. The company's lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, aimed at treating congestion in patients with decompensated heart failure. Additionally, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic targeting infections from both gram-positive and gram-negative organisms, and a carbapenem program for addressing gram-negative infections. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals emphasizes the importance of subcutaneous drug administration, offering a convenient two-component delivery system that allows for patient self-administration, thereby providing a safer and more comfortable alternative to traditional intravenous methods. The company collaborates with West Pharmaceutical Services to enhance its SmartDose system, furthering its mission to improve patient outcomes.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Biom'Up S.A. is a French company specializing in the development and commercialization of innovative hemostatic products and absorbable medical devices based on patented biopolymer and collagen technologies. Founded in 2005 and headquartered in Saint-Priest, France, Biom'Up designs and manufactures medical devices aimed at improving surgical outcomes across various specialties, including orthopedic, spinal, cardiac, general, and maxillofacial surgeries. Its flagship products, such as HEMOBLAST bellows and associated laparoscopic applicators, are clinically proven to enhance patient healing by facilitating guided regeneration of soft tissues and bone. The company markets its products primarily in Europe and the United States, contributing significantly to the field of biosurgery.

SANIFIT is a biotechnology company developing treatments for calcification disorders, including progressive vascular calcification and cardiovascular diseases linked to calcification in patients with end-stage renal disease on hemodialysis. It operates as a clinical-stage biopharmaceutical company focused on therapies to prevent or treat calcium-related pathologies that contribute to heart disease in dialysis patients.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Vtesse, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, focused on developing treatments for patients with rare diseases. The company is primarily engaged in the clinical study of VTS-270 for the treatment of Niemann-Pick Disease Type C (NPC) and is also involved in the pre-clinical discovery and development of additional novel drugs for NPC and other lysosomal storage diseases. Vtesse operates as a subsidiary of Sucampo Pharmaceuticals, Inc. and is recognized as the first spin-out from Cydan Development, Inc., an orphan-drug accelerator. The company collaborates with the National Institutes of Health (NIH) to advance its clinical programs and is supported by a seasoned management team with extensive experience in drug development. Vtesse's initiatives aim not only to provide innovative therapies but also to offer resources and support for patients and families affected by NPC and related conditions.

Ziarco, Inc. is a biotechnology company founded in 2012 and headquartered in Palo Alto, California. The company specializes in the development of therapeutic agents aimed at treating inflammatory and allergic diseases. Its primary focus is on inflammatory skin disorders, and it has established a product pipeline that includes a histamine H4 receptor antagonist program. This program targets various therapeutic areas, such as asthma, allergic rhinitis, pruritus, and skin diseases, providing innovative treatment options for conditions like atopic dermatitis and psoriasis. Through its research and development efforts, Ziarco aims to offer effective solutions for patients suffering from these challenging health issues.

Founded in 2003, Atox Bio is a biotechnology company specializing in immunomodulators for treating critically ill patients with severe infections. Its focus lies in developing novel modulators targeting key pathways of the adaptive and innate immune response to improve outcomes in critical care settings.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic products, particularly for patients with serious medical conditions. The company's lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, aimed at treating congestion in patients with decompensated heart failure. Additionally, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic targeting infections from both gram-positive and gram-negative organisms, and a carbapenem program for addressing gram-negative infections. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals emphasizes the importance of subcutaneous drug administration, offering a convenient two-component delivery system that allows for patient self-administration, thereby providing a safer and more comfortable alternative to traditional intravenous methods. The company collaborates with West Pharmaceutical Services to enhance its SmartDose system, furthering its mission to improve patient outcomes.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, that specializes in the development of novel therapeutics for skin disorders. Founded in 2011, the company is dedicated to creating innovative treatments for dermatological conditions, particularly atopic dermatitis and acne. Unlike many competitors who primarily focus on reformulating existing medications with limited advancements, Thesan aims to discover and develop new chemical entities that promise substantially improved therapeutic options for patients. This commitment to innovation addresses the growing need for effective solutions in a field that has seen relatively little progress in recent years.

VHsquared Ltd. is a biotechnology company focused on developing oral biologics for immuno-inflammatory conditions affecting the gastrointestinal tract. Founded in 2010 and based in Cambridge, United Kingdom, VHsquared utilizes its proprietary Vorabody platform to create engineered domain antibodies that are resistant to degradation in the gut, allowing for effective oral administration. This innovative approach addresses the limitations of conventional antibodies, which are typically broken down in the gastrointestinal system. The company aims to produce a range of functional food products that target gastrointestinal infections and immune-mediated diseases, leveraging advancements in mucosal immunology and microbiota analysis. By developing therapies that are stable, specific, and locally active, VHsquared seeks to provide safer, more effective treatment options for patients with inflammatory bowel diseases and related conditions.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The company identifies and de-risks compounds that hold therapeutic and commercial potential, employing a rigorous process to generate data that supports both development pathways and the formation of new companies. With a team that boasts deep expertise in drug development and strong relationships within academia and patient advocacy, Cydan accelerates therapies through various stages, including clinical, regulatory, and commercial development. By facilitating the creation of effective treatments, Cydan aims to improve the lives of patients and families affected by rare diseases.

Acacia Pharma is a pharmaceutical company dedicated to discovering and developing supportive care drugs. Its primary focus is on cancer supportive care, with products including BAREMSIS for post-operative nausea and vomiting, APD403 for chemotherapy-induced nausea and vomiting, and BYFAVO for sedation during invasive medical procedures. The company serves anesthesiologists and oncologists, aiming to improve the care of patients undergoing serious medical treatments.

DYSIS Medical Ltd., established in 2002 and headquartered in Edinburgh, UK, specializes in designing, developing, manufacturing, and marketing non-invasive imaging systems for detecting cancerous and pre-cancerous lesions. Its flagship product is the DYSIS Colposcope, a digital colposcope that measures aceto-whitening reaction and generates an intuitive map for easier diagnosis. The company also offers accessories like disposable/reusable specula, diathermy loops, coagulation balls, and software for data management and DYSISmap development. With sales offices in Tampa (USA), Edinburgh (UK), and Athens (Greece), DYSIS Medical aims to improve healthcare outcomes globally.

River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

BONESUPPORT AB is a medical technology company based in Lund, Sweden, specializing in the development of injectable bioceramic bone graft substitutes aimed at treating fractures and bone voids resulting from trauma, infection, disease, or surgery. Founded in 1999, the company offers a range of products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V. These products are designed to address various medical conditions such as chronic osteomyelitis and infected diabetic foot ulcers. CERAMENT G and CERAMENT V are antibiotic-eluting bone graft substitutes that enhance bone healing, utilizing gentamicin and vancomycin, respectively. BONESUPPORT operates additional locations in Frankfurt, Zurich, London, Boston, and Haryana, India, and is committed to improving the quality of life for patients with bone disorders through innovative biomaterial solutions.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Acacia Pharma is a pharmaceutical company dedicated to discovering and developing supportive care drugs. Its primary focus is on cancer supportive care, with products including BAREMSIS for post-operative nausea and vomiting, APD403 for chemotherapy-induced nausea and vomiting, and BYFAVO for sedation during invasive medical procedures. The company serves anesthesiologists and oncologists, aiming to improve the care of patients undergoing serious medical treatments.

Nexstim specializes in non-invasive brain stimulation technologies, focusing on navigated transcranial magnetic stimulation (TMS) for therapeutic and diagnostic applications. Its proprietary SmartFocus technology enables accurate targeting of specific brain areas. Nexstim's primary products are the NBT system for treating major depression or chronic pain, and the NBS system for pre-surgical brain mapping. Headquartered in Helsinki, Finland, Nexstim serves customers globally.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Asante Solutions is a medical device company founded over a decade ago in Denmark, specializing in the development of innovative solutions for diabetes management. The company initially garnered support from a select group of European venture capitalists, facilitating the early-stage development of its flagship product, the Pearl Insulin Pump. This device is designed to improve and simplify insulin delivery for diabetic patients through a system that utilizes pre-filled insulin cartridges, allowing for a more modern and efficient method of insulin administration. Asante Solutions aims to enhance the quality of life for individuals managing diabetes by providing advanced medical devices tailored to their needs.